Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company's lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmune diseases and relapsed/refractory B-cell non-hodgkin's lymphoma. It also develops ADI-270, an armored gamma delta CAR T cell product candidate to treat multiple CD70+ solid tumor and hematological malignancies indications, with renal cell carcinoma. The company was founded in 2014 and is based in Boston, Massachusetts.

Adicet Bio Inc.

Wedbush analyst reiterated a Buy rating on Adicet Bio today and set a price target of $25.00. The word on The Street in general, suggests a Strong ...

Wedbush Sticks to Its Buy Rating for Adicet Bio (ACET)

Adicet Bio ( ($ACET) ) just unveiled an update. On April 27, 2026, Adicet Bio, Inc. entered into an exchange agreement with RA Capital Management, ...

Current Quarter	$-2.42	Next Quarter	$-2.03
Current Year	$-8.61	Next Year	$-3.71
QoQ Growth	+16.1%	YoY Growth	+56.9%
3Y EPS CAGR	+14.6%	Target Price	$34.83
Consensus	Buy	Upside	+318.1%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ACET	$8.33	+0.36%	90.23K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ACET	$8.33	+0.4%	90.23K
3
4
5
6

ACET

ACET

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Adicet Bio Inc. Data in Excel

Get Adicet Bio Inc. Data in Excel